EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Corbion NV (CRBN) fair value: what the stock is really worth

As of Sep 23, 2026: fair value of Corbion NV €16.57, price €22.38, upside -26.0%, quality 64 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? Yes
  3. Add to watchlist

Basic Materials · NL · ISIN NL0010583399

CN Corbion NV logo Broad data Sep 23, 2026

Corbion NV

CRBN · AS

Overvalued / MonitorQuality is not strong enough to offset the price risk.

!Fair value €16.57 · Overvalued (−26%)
!Quality 64/100
!Mixed Growth (revenue YoY −1.6 %/yr)
!Thin margins · 5.9% net margin (TTM)
✓Low debt · generates free cash flow
·2.86% dividend yield
✓Ranks above peers (10/15)
!Narrow moat 44/100
!Insider activity 45/100
Watch Corbion NV for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

€40.59 €14.27 Fair Value €16.57 Jul 2021 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 23, 2026.

How to read this chart

60‑month range €14.27 – €40.59 · fair‑value band €11.24 – €23.68 · the €22.38 price screens above the €16.57 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 2 fiscal years are left out: there the valuation rested on only a fraction of the usual models. Dashed = 300-day average. As of Sep 23, 2026.

Follow Corbion in your weekly email

Every Wednesday you see whether Corbion is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Corbion N.V. provides lactic acid and derivatives, food preservation solutions, functional ingredient systems, and algae-derived nutritional ingredients in the Netherlands, the United States, Asia, rest of Americas, the rest of Europe, the Middle East, and Africa. It operates in two segments, Functional Ingredients & Solutions, and Health & Nutrition.

Show more

Corbion N.V. provides lactic acid and derivatives, food preservation solutions, functional ingredient systems, and algae-derived nutritional ingredients in the Netherlands, the United States, Asia, rest of Americas, the rest of Europe, the Middle East, and Africa. It operates in two segments, Functional Ingredients & Solutions, and Health & Nutrition. The company offers antioxidants, fermentation and preservation ingredients, flavors, fortification, functional blends, and lactic acid lactates and derivatives; AlgaPrime DHA, an omega-3 sourcing product; AlgaVia which develops foods and beverages with reduced saturated fat content; CALFEED, a dry lactic acid source to boost feed intake for swine or poultry; LAFEED that helps feed intake and digestive health; LAFEED Powder that acts as a preservative and acidulate; PURAC DW, provides an acidifier, preservative, and antimicrobial in teat-dip applications for animals; PURAC Pet food; PURASOLV; and PURASOLV EL. It also provides PURASORB polymers for medical and pharmaceutical industries; PURASOLV solvents; PURALACT B3 for resin and coating performance; personal care products, such as ESTERLAC Emulsifiers and Surfactants, GLUCONAL ZN, PURAC BF/P41, PURAC HiPure 90, PURAC UltraPure, PURACAL PP/USP, PURAMEX ZN, PURASAL MOISTXS, PURASAL NH/COS, PURASAL S/HQ60, and PURASOLV EL; and GLUCONAL, PURAC PF, PURACAL, PURAMEX, and PURASAL S/PF. In addition, the company offers food solutions, including acidification, color retention, decontamination, food safety and preservation, freshness and shelf life, health and nutrition, strengthening conditioning and texturizing, and taste and texture; PURASORB R&D; biochemical specialties solutions comprising solvency, antimicrobial, moisturization, and pharma; and Algae ingredients solutions. The company was formerly known as CSM N.V. and changed its name to Corbion N.V. in October 2013. Corbion N.V. was founded in 1903 and is headquartered in Amsterdam, the Netherlands.

Stock analysis

Corbion NV (CRBN) currently trades at €22.38, while our model-based Fair Value estimate is €16.57, implying the stock looks roughly 35.1% overvalued today.

Show more

Valuation

Bull case: the Multiples group reads highest at a median of €22.07 per share, and 3 of the 24 models we run sit above the €22.38 price.

Bear case: the Dividend Discount group reads lowest at €5.41, and 21 of the 24 models stay below the price. Evidence for this calculation is high.

Scenario range: €11.24 (bear) to €23.68 (bull), the price of €22.38 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 64/100 (solid quality), in the Basic Materials sector.

Mixed Growth: Spin-off in 2024: revenue and profit before it include the divested business. Growth is measured afresh from 2024.

Corbion NV reported revenue of €1.3B in FY2025 versus €1.1B in FY2021, a compound +4.3%/yr. Reported net income was €74.8M in FY2025, compounding −1.1%/yr from FY2021.

Key figures

Market cap €1.3B · P/E ratio 17.6 · P/S ratio 1.04 · EPS (TTM) €1.27 · Dividend yield 2.9% · Net margin 5.9% · Return on equity 9.9% · Return on assets (EBIT) 6.0%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 48 out of 100 (low confidence).

What moves the price

The share trades about 1% below its 52-week high and 42% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Basic Materials peers we cover trades at −48% fair-value upside, at −26%, CRBN screens cheaper than that median.

Fair Value models

Bear €11.24 Fair Value €16.57 Bull €23.68
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then (€0.4608 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
FCF DCF €11.01 €15.72 €23.68 78
Growth DCF €11.51 €15.98 €22.95 76
Owner Earnings €10.97 €15.66 €23.61 74
All 24 models by family
DCF Models
FCF DCF €11.01 €15.72 €23.68 78
Owner Earnings €10.97 €15.66 €23.61 74
5Y Revenue Exit €11.70 €19.05 €29.77 69
5Y EBITDA Exit €14.89 €24.56 €37.40 72
5Y P/E Exit €10.18 €16.43 €23.93 68
10Y Revenue Exit €10.89 €16.02 €21.52 65
10Y EBITDA Exit €13.06 €19.14 €25.63 67
10Y P/E Exit €10.45 €14.53 €18.37 63
Earnings-Based
Graham-Dodd €8.83 €11.07 €12.54 65
EPV €8.73 €10.55 €12.07 74
Dividend Discount
Gordon GGM €5.02 €5.41 €5.99 67
DDM Multi-Stage €5.02 €6.00 €7.25 65
Multiples
P/E Multiple €16.55 €22.07 €27.58 63
P/S Multiple €16.55 €22.07 €27.58 58
P/B Multiple €16.55 €22.07 €27.58 55
EV/EBIT €16.57 €23.65 €30.72 65
EV/EBITDA €21.67 €30.45 €39.22 67
EV/Revenue €13.74 €21.62 €29.51 53
Asset-Based
NCAV (Graham) €6.44 €8.63 €12.89 54
Growth DCF
Growth DCF €11.51 €15.98 €22.95 76
Rev-Margin DCF €11.70 €19.47 €29.01 69
Economic Profit
Residual Income €10.72 €11.66 €13.94 74
ROIC Compounder €8.73 €10.55 €12.07 70
Growth Earnings
Growth-Adj P/E €11.79 €16.84 €21.90 65

Open the full fair value analysis →

Notify me when CRBN reaches fair value

Put CRBN on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 64/100

Of which business quality 62 · Market factors (momentum, volatility) 73

Profitability 45
Margins and returns on capital today
Quality Growth 47
Are margins and returns improving?
Cashflow 57
Earnings quality: real cash, not paper profit
Fin. Strength 59
Balance sheet, leverage, solvency risk
Investment 84
Disciplined investing over empire-building
Low Volatility 72
Calm price path (market factor)
Momentum 64
Price trend over the last 3–12 months (market factor)
52W Momentum 88
Distance to the 52-week high (market factor)
Net Issuance 96
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 55/100
Spin-off in 2024: revenue and profit before it include the divested business. Growth is measured afresh from 2024.
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
+3.9%
Earnings growth per share plus dividend.
Earnings per share, growth per year+1.0%
Dividend (yield on the price)2.9%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.1% vs −2%, steady
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.11% → 9%
Start year 2020 (pandemic)

Growth Forecast

A lot of optimism in the price
The price assumes more growth than the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+10.1%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+3.0%
Yearly sales growth analysts expect, extended to five years.
After inflation (euro area: IMF forecast 2.2% a year to 2030, 2.6% from 2016 to 2025) that is about +7.8% a year for the price and +0.8% for the forecasts.
Forecast 2026 (sales)+0.6%
Forecast 2027 (sales)+4.0%
Projected 2028 (sales)+3.8%
Projected 2029 (sales)+3.5%
Projected 2030 (sales)+3.3%

CRBN screens 35% overvalued. Compare with Linde plc →

Compare Corbion NV with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Specialty Chemicals · 706 stocks

Beats the industry median on 10/15 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 64 · Top 25%
Fair Value upside −27% · Below median
Profitability
Return on equity (TTM) 10% · Above median
Return on assets 5% · Above median
Net margin (TTM) 6% · Above median
Operating margin (TTM) 9% · Above median
Growth and dividend
Revenue growth −5% · Below median
Dividend yield (TTM) 2.9% · Above median
Balance sheet
Debt / equity 0.42× · Highest 25%

Valuation Multiplesvs Specialty Chemicals median · lower = cheaper

P/E (TTM) 17.6× · Cheaper than median
P/B 2.00× · Pricier than median
P/S (TTM) 1.18× · Cheaper than median
P/FCF 16.1× · Priciest 25%
EV/EBITDA 9.4× · Cheaper than median
PEG 1.26× · Cheaper than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 0
FUTURE (revenue growth)0 · sector 21
PAST (return on equity)39 · sector 23
HEALTH (low debt)79 · sector 95
DIVIDEND (yield)57 · sector 29

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Specialty Chemicals stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Linde plc LIN $464.91 $441.28 −5%
The Sherwin-Williams Company SHW $328.35 $148.97 −55%
Ecolab Inc ECL $276.22 $96.18 −65%
Air Products and Chemicals, Inc APD $287.86 $122.14 −58%
Givaudan SA GIVN CHF 3,464 CHF 1,523 −56%
Wanhua Chemical Group 600309 ¥70.66 ¥68.03 −4%
Sika AG SIKA CHF 188.90 CHF 98.89 −48%
Asian Paints Limited ASIANPAINT ₹2,449 ₹1,479 −40%
PPG Industries, Inc PPG $107.77 $77.06 −28%
DSM-Firmenich AG DSFIR CHF 91.50 CHF 29.27 −68%

Explore undervalued stocks

More undervalued Basic Materials stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Corbion NV · Fair Value
€16.57 −35%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Corbion NV Fair Value". https://www.fairvalue-calculator.com/stock/CRBN

Frequently asked questions

Is Corbion NV (CRBN) overvalued or undervalued?
As of Sep 23, 2026, our model estimates a fair value of €16.57 versus a price of €22.38, about −26% upside (overvalued).
What is the fair value of CRBN?
Our model-based fair value for Corbion NV is €16.57 (as of Sep 23, 2026), built from audited fundamentals. The current price: €22.38.
What is the quality score of CRBN?
Corbion NV has a Quality Score of 64/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Corbion NV (CRBN)?
Our model-based price target is the fair value of €16.57 (as of Sep 23, 2026) from 24 valuation models. Cautious scenario €11.24, optimistic scenario €23.68. It is a calculation from audited fundamentals, not an analyst target.
What is the Corbion NV stock forecast for 2026?
Our models put fair value at €16.57, about −26% upside versus a price of €22.38 (overvalued). Cautious scenario €11.24, optimistic scenario €23.68. The calculation is refreshed regularly with new filings.
What is the revenue of Corbion NV (CRBN)?
Corbion NV reported trailing-twelve-month revenue of about €1.3B (latest available figure, as of Sep 23, 2026).
Does Corbion NV pay a dividend?
Corbion NV currently shows a dividend yield of about 2.86% relative to its recent price (as of Sep 23, 2026).
What growth is priced into Corbion NV (CRBN)?
For today's price to be fair in a discounted-cash-flow model, Corbion NV would have to grow free cash flow by +10.1 % per year for five years (discount rate 10.8 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +5.1 % per year. As of Sep 23, 2026.
What discount rate (WACC) does the fair value of CRBN use?
Our models discount Corbion NV at 10.8 %: a base by market capitalisation (small), damped by beta 0.94, country premium for Netherlands. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Corbion NV that is +10.1 % per year a year over ten years, using the same discount rate (10.8 %) and the same formula as our fair value.
How much growth has Corbion NV (CRBN) delivered so far?
Over the past 5 years revenue at Corbion NV grew +5.1 % a year. The price currently implies +10.1 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Corbion NV (CRBN) growing?
The median revenue growth in the sector is +3.3 % a year. That is the yardstick for the growth priced into Corbion NV (+10.1 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Corbion NV (CRBN)?
The free-cash-flow yield on the price is 7.14 %: that much free cash flow Corbion NV produces per unit of market value. When it exceeds the discount rate of our models (10.8 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Corbion NV (CRBN)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Corbion NV it is €16.57 per share (as of Sep 23, 2026), against a price of €22.38. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).
Is Corbion NV stock overvalued or undervalued in 2026?
As of Sep 23, 2026, CRBN trades above its calculated fair value: price €22.38, fair value €16.57, a gap of about −26% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of CRBN?
No. The price is what the market pays today (€22.38); the fair value is what the company's own numbers justify (€16.57). For Corbion NV the two are €5.81 per share apart. That gap is exactly why we show both numbers side by side.
How much is Corbion NV worth?
The market values Corbion NV at about €1.3B (market capitalisation, as of Sep 23, 2026). Per share that is €22.38; our models calculate a fair value of €16.57 per share.
What do the bullish and bearish scenarios say about CRBN?
Our models span a range for Corbion NV: cautious scenario €11.24, base €16.57, optimistic €23.68 per share (as of Sep 23, 2026, price €22.38). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of CRBN?
Corbion NV trades at a price-to-earnings ratio of 17.6 (as of Sep 23, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of €16.57 is built from several models across several years. Other multiples: PEG 1.3, P/B 2.0, P/S 1.2, EV/EBITDA 9.4.
What is the PEG ratio of CRBN?
The PEG ratio of Corbion NV is 1.26 (P/E divided by earnings growth, as of Sep 23, 2026). That is above 1, so the growth is already paid for in the price.
How solid is the balance sheet of Corbion NV (CRBN)?
Balance-sheet figures for Corbion NV (as of Sep 23, 2026): return on equity 9.9%, debt of 0.42 per unit of equity. They feed the Quality Score of 64/100, which measures business quality independently of the share price.
How far is CRBN from its 52-week high?
Corbion NV trades at €22.38, about 1% below its 52-week high of €22.66 and 42% above the low of €15.80 (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of €16.57 is for.
Which stocks are comparable to Corbion NV?
From the same area (Basic Materials) we also value Linde plc, The Sherwin-Williams Company, Ecolab Inc, Air Products and Chemicals, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Corbion NV stock attractive at the current price?
The data as of Sep 23, 2026: price €22.38, calculated fair value €16.57 (−26%), Quality Score 64/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of CRBN calculated?
We run Corbion NV through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of €16.57, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.1 % above its aggregate fair value. Corbion NV itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Corbion NV (CRBN)?
The closing price on Sep 23, 2026 was €22.38. Our model-based fair value is €16.57, about −26% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Corbion NV right now?
Solid but not exceptional quality (64/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range (€11.24 to €23.68) leaves room in how you read the outcome.
Where does the earnings growth of Corbion NV (CRBN) come from?
Earnings per share at Corbion NV grew +2.7 % a year from 2015 to 2025. Broken into its drivers: revenue per share +4.7 %, EBIT margin −6.7 %, tax rate +0.5 %, residual (interest, one-offs) +4.6 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.

Key figures of Corbion NV

How large is the market capitalisation of Corbion NV (CRBN)?
The market capitalisation of Corbion NV is €1.3B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Corbion NV (CRBN)?
The price-to-sales ratio of Corbion NV is 1.04 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Corbion NV (CRBN)?
Earnings per share at Corbion NV are €1.27 (price ÷ EPS = P/E 17.6). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Corbion NV (CRBN)?
The dividend yield of Corbion NV is 2.9% (payout 50.4%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Corbion NV (CRBN)?
The net margin of Corbion NV is 5.9% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Corbion NV (CRBN)?
The return on equity (ROE) of Corbion NV is 9.9% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Corbion NV (CRBN)?
On an EBIT basis the return on assets of Corbion NV is 6.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Corbion NV (CRBN)?
The operating margin of Corbion NV is 8.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Corbion NV (CRBN)?
Revenue at Corbion NV is growing −4.5% versus a year earlier (3y avg −4.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Corbion NV (CRBN)?
Earnings per share at Corbion NV are growing +37.5% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Corbion NV (CRBN) carry?
The net debt of Corbion NV is €436M (fiscal year 2025, ≈ 4.7 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Corbion NV in the live analysis

One click puts Corbion NV on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.